Search research articles
Contact Us
Filters
Showing results (81-90 of 130) with videos related to
Page
of 13
Sort By:
Cancer Discovery
|
November 8, 2015
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy
Manish Neupane, Allison P Clark, Serena Landini, et al.
JNCI Cancer Spectrum
|
May 13, 2021
Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)
Jennifer A Ligibel, Luke Huebner, Hope S Rugo, et al.
Molecular Cancer Therapeutics
|
February 22, 2012
Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer
Mickey K Kim, Takuya Osada, William T Barry, et al.
Plos One
|
April 3, 2008
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer
Kelly H Salter, Chaitanya R Acharya, Kelli S Walters, et al.
Journal of the National Cancer Institute
|
June 27, 2015
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)
Jennifer A Ligibel, Constance T Cirrincione, Minetta Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2009
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia
Daphne R Friedman, J Brice Weinberg, William T Barry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2016
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Maura N Dickler, William T Barry, Constance T Cirrincione, et al.
NPJ Breast Cancer
|
August 8, 2018
Unraveling the clinicopathological features driving the emergence of <i>ESR1</i> mutations in metastatic breast cancer
Yanan Kuang, Bilal Siddiqui, Jiani Hu, et al.
The AAPS Journal
|
June 17, 2017
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, et al.
Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology
|
March 21, 2022
Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure
Michael D Schwartz, Robert Raulli, Judith W Laney, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 130) with videos related to
Sort By:
Page
of 13
Cancer Discovery
|
November 8, 2015
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy
Manish Neupane, Allison P Clark, Serena Landini, et al.
JNCI Cancer Spectrum
|
May 13, 2021
Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)
Jennifer A Ligibel, Luke Huebner, Hope S Rugo, et al.
Molecular Cancer Therapeutics
|
February 22, 2012
Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer
Mickey K Kim, Takuya Osada, William T Barry, et al.
Plos One
|
April 3, 2008
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer
Kelly H Salter, Chaitanya R Acharya, Kelli S Walters, et al.
Journal of the National Cancer Institute
|
June 27, 2015
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)
Jennifer A Ligibel, Constance T Cirrincione, Minetta Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2009
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia
Daphne R Friedman, J Brice Weinberg, William T Barry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2016
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Maura N Dickler, William T Barry, Constance T Cirrincione, et al.
NPJ Breast Cancer
|
August 8, 2018
Unraveling the clinicopathological features driving the emergence of <i>ESR1</i> mutations in metastatic breast cancer
Yanan Kuang, Bilal Siddiqui, Jiani Hu, et al.
The AAPS Journal
|
June 17, 2017
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, et al.
Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology
|
March 21, 2022
Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure
Michael D Schwartz, Robert Raulli, Judith W Laney, et al.
Page
of 13